CD24, CD27, CD36 and CD302 gene expression could also be combined with a flow cytometry approach using the PrimeFlow® RNA Assay to develop a powerful tool for risk stratification and outcome prediction in MM. This evidence concerns the gene CD302 and Miyoshi myopathy.